Results 271 to 280 of about 6,578,993 (340)

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) is a central biomarker in multiple myeloma (MM), offering unprecedented sensitivity for evaluating treatment efficacy and serving as a potential surrogate endpoint. We conducted a comprehensive analysis of clinical trials registered on ClinicalTrials.gov between 2014 and 2025.
Mimi Choon‐Quinones, George Dennis Obeng, Benjamin Asiedu‐Ayeh, Sampson Kawuo, Asmau Mohammed Tukur, Inusah Mohammed, Akosua Pokuaah Obeng, Jean‐Luc Harousseau, Anja Seckinger, Dirk Hose, Emmanuel Sarkodie, Attila Imre, Marcell Csanádi   +12 more
wiley   +1 more source

Identification of ceRNA Regulatory Networks Driven by the lncRNA NEAT1 in Multiple Myeloma. [PDF]

J Cell Mol Med
Ronchetti D, Traini V, Silvestris I, Fabbiano G, Devecchi A, Torricelli F, Puccio N, Craparotta I, Bolis M, Piva R, Neri A, Agnelli L, Passamonti F, Bolli N, Taiana E.   +14 more
europepmc   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, EarlyView.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

MULTIPLE MYELOMA

Annals of Surgery, 1931
openaire   +3 more sources

Elranatamab Exposure-Safety Analysis in Relapsed or Refractory Multiple Myeloma. [PDF]

J Clin Pharmacol
Soltantabar P, Hibma J, Wang D, Conte U, Hickman A, Elmeliegy M.   +5 more
europepmc   +1 more source

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

European Journal of Haematology, EarlyView.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso, S. Masci, M. Talarico, A. Vitale, S. Barbato, V. Solli, M. Puppi, I. Rizzello, L. Pantani, P. Tacchetti, M. Iezza, R. Restuccia, I. Sacchetti, E. Manzato, S. Ghibellini, S. Armuzzi, B. Taurisano, M. Cavo, E. Zamagni   +18 more
wiley   +1 more source

The SCARLET Trial: Radiotheranostics in Multiple Myeloma. [PDF]

Radiol Imaging Cancer
Jain S, Graham MM.
europepmc   +1 more source

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort Study. [PDF]

Hematol Oncol
Vaxman I, Zamir I, Cohen I, Fridberg G, Shragai T, Trestman S, Baran TZ, Luttwak E, Shmuel R, Melamed N, Levy S, Avivi I, Raanani P, Dispenzieri A, Gertz MA, Cohen YC.   +15 more
europepmc   +1 more source